Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results(For the Second Quarter ended September 30, 2023) [Under Japanese GAAP]
November 8, 2023
Tokyo Stock Exchange
Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL (03) 3525-4701
Scheduled date for submitting quarterly report: November 14, 2023
Scheduled date for starting dividend payment: December 4, 2023
Supplementary Materials Prepared for the Quarterly Financial Statements: Yes
Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investor, securities analysts)(Amounts rounded down to the nearest million yen)
1. Consolidated Results for Six Months Ended September 30, 2023 (From April 1, 2023, to September 30, 2023)(1) Consolidated Operating Results(Percentage changes relative to previous corresponding period)
Profit attributable toNet sales
Operating profit
Ordinary profit
owners of parent
Six months ended Million yen% Million yen% Million yen% Million yen%
September 30, 2023
54,937
11.9
1,144
47.2
1,387
18.4
1,757
41.4
September 30, 2022
49,093777—1,171
309.8
1,242
921.1
－0.0(Note) Comprehensive income: For six months ended September 30, 2023: 2,309 million yen (10.8%),
For six months ended September 30, 2022: 2,084 million yen (— %)Basic earnings
per share

Six months ended
September 30, 2023
September 30, 2022

Yen
30.66
21.69

(2) Consolidated Financial Position
Total assets
As ofSeptember 30, 2023
March 31, 2023

Diluted earnings
per share

Yen——Net assets

Million yen
176,175
176,045

Equity ratio

Million yen
126,226
125,461

%
71.6
71.3

(Note) Equity: As of September 30, 2023: 126,226 million yen, As of March 31, 2023: 125,461 million yen

2. Dividends
Annual dividends per share(Record date)Fiscalyear-end

First quarter-end

Second quarter-end

Third quarter-endYenYenYenYenYen

—

32.00

52.00

—

32.00

52.00

Fiscal year ended—
20.00
March 31, 2023
Fiscal year ending—
20.00
March 31, 2024
Fiscal year ending
March 31, 2024
(Forecast)(Note) Whether the most recent dividend forecast has been revised: NoTotal

3. Forecast of Consolidated for the Year Ending March 31, 2024 (From April 1, 2023, to March 31, 2024)(Percentage changes relative to previous corresponding period)
Profit attributable to Earnings
Net sales
Operating profit
Ordinary profit
owners of parentper share
Million yen% Million yen% Million yen% Million yen%Yen
Full year
116,200
2.6
6,000
17.1
6,500
11.5
4,900
3.7
85.51
(Note) Whether the most recent earning forecast have been revised: No1

4. Other(1) Changes in major subsidiaries during the period(Change of specified subsidiaries associated with a change of the scope of consolidation): Yes
Newly included: None
Excluded:
1 company (The former Kyorin Pharmaceutical Co. Ltd.)(2) Application of special accounting methods in the preparation of quarterly financial statements : Yes(3) Changes in accounting policies, changes in accounting estimates and restatements(i) Changes due to mandatory changes of accounting standards: None(ii) Changes other than i): None(iii) Changes in accounting estimates: Yes(iv) Restatements: None(4) Number of shares issued (common stock)(i) Number of shares issued and outstanding at the end of the fiscal year (including treasury stock)
As of September 30, 2023: 64,607,936 shares,Fiscal year ended March 31 2023: 64,607,936 shares(ii) Number of shares of treasury stock at the end of the fiscal year
As of September 30, 2023: 7,159,060 shares,
Fiscal year ended March 31 2023: 7,304,066 shares(iii) Averaged number of shares of during the period
As of September 30, 2023: 57,329,937 shares,
As of September 30, 2022: 57,302,263 shares* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.
* Explanations about the appropriate use of the business forecasts and other noteworthy points.
These forecast performance figures are based on information currently available to the Company and may include
uncertain factors or risk that affect our future performance. Accordingly, actual business results may materiallydiffer from the forecasted figures due to various factors in the future.
(Methods for obtaining supplementary materials and content of financial results disclosure)
Supplementary materials will be made available on the Company’s website in conjunction with the Summary ofConsolidated Financial Results.

2